Author

K. M. Bailey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Organism:human· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

E. Mukherjee· 2 shared J. D. Daley· 2 shared A. C. Olson· 1 shared A. C. Tufino· 1 shared A. P. Hinck· 1 shared A. R. Cillo· 1 shared C. Hinck· 1 shared C. Kumar-Sinha· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Mukherjee

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Immunocompetent murine model of Ewing sarcoma reveals role for TGFβ inhibition to enhance immune infiltrates in Ewing tumors during radiation

J. D. Daley, E. Mukherjee, A. C. Tufino, N. Bailey, S. Bhaskar, N. Periyapatna, I. MacFawn, S. Kunning, C. Hinck, T. Bruno, A. C. Olson, L. M. Mcallister, A. P. Hinck, K. Cooper, R. Bao, , K. M. Bailey

The paper develops an immunocompetent mouse model of Ewing sarcoma to show that TGFβ inhibition enhances immune infiltration and reduces metastasis during radiation therapy.

bioRxiv · May 7, 2024 · PreprintCancer Biology

PARP inhibition in Ewing sarcoma: impact of germline DNA damage repair defects and activation of immunoregulatory pathways

L. M. Maurer, R. E. Venier, E. Mukherjee, C. M. Julian, J. D. Daley, N. G. Bailey, M. F. Jacobs, C. Kumar-Sinha, H. Raphel, K. Weiss, K. A. Janeway, R. Mody, P. C. Lucas, L. M. McAllister-Lucas, K. M. Bailey

This study shows that Ewing sarcoma cells with germline BARD1 mutations are sensitive to PARP inhibitors and that PARP inhibition increases PD-L1 expression, suggesting potential for combination immunotherapy.

bioRxiv · Sep 18, 2020 · PreprintCancer Biology